ChloroquineV1, Main, Exploration, bibRecord, 001F45

Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases

Identifieur interne : 001F45 ( Main/Exploration ); précédent : 001F44; suivant : 001F46

Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases

Auteurs : Kam Hon Yoon [Singapour]

Source :

APLAR Journal of Rheumatology [ 0219-0494 ] ; 2004-05.

RBID : ISTEX:34E26F591602D0871E1EC31B9D3729D0F17020C1

English descriptors

Teeft :
- Adjuvantinduced arthritis, Adverse events, Antiphospholipid syndrome, Aplar journal, Arthritis, Arthritis rheum, Azathioprine, Azathioprine steroids, Chinese woman, Conventional therapy, Creatinine, Cutaneous manifestations, Cutaneous vasculitis, Cyclosporin, Disease conditions, Gastrointestinal symptoms, Good response, Immunosuppressive agents, Interstitial lung disease, Liver dysfunction, Liver function test, Lupus, Lupus erythematosus, Lupus nephritis, Malar rash, Mycophenolate, Mycophenolate steroids, National university hospital, Nephritis, Normal range, Partial responders, Patient example, Pediatric patients, Period november, Prednisolone, Psoriatic, Psoriatic arthritis, Renal biopsy, Renal transplantation, Resistant diseases, Rheum, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatology, Successful usage, Systemic lupus erythematosus, Tacrolimus, Topical tacrolimus.

Abstract

Aim: This study reports the first successful usage of tacrolimus in various resistant or relapsed rheumatic diseases in Asian patients Methods: This is an open prospective study of the efficacy of tacrolimus for patients with various relapsed/resistant rheumatic diseases who were intolerant of or failed conventional therapy. Patients were enrolled in the study from the period November 2001 to September 2002. Results: A total of 20 patients were included in the study. Their disease conditions were as follows: SLE with relapsed lupus nephritis (six patients); SLE with antiphospholipid syndrome (APS) (two patients); rheumatoid arthritis (five patients); psoriatic arthritis (three patients); scleroderma (two patients); anti–Jo−1 syndrome (two patients). Improvement in their conditions were noted in all but one patient who was intolerant to tacrolimus. Conclusions: Tacrolimus (FK506) is a new armamentarium that can be added to the choice of immunosuppressive agents for rheumatologists, especially for those patients with severe or resistant diseases.

Url:

https://api.istex.fr/ark:/67375/WNG-BLJC5B5D-J/fulltext.pdf

DOI: 10.1111/j.1479-8077.2004.00064.x

Affiliations:

Singapour

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 000837
to stream Istex, to step Curation: 000837
to stream Istex, to step Checkpoint: 000D86
to stream Main, to step Merge: 001F60
to stream Main, to step Curation: 001F45

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title>
<author><name sortKey="Yoon, Kam Hon" sort="Yoon, Kam Hon" uniqKey="Yoon K" first="Kam Hon" last="Yoon">Kam Hon Yoon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:34E26F591602D0871E1EC31B9D3729D0F17020C1</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1111/j.1479-8077.2004.00064.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-BLJC5B5D-J/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000837</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000837</idno>
<idno type="wicri:Area/Istex/Curation">000837</idno>
<idno type="wicri:Area/Istex/Checkpoint">000D86</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D86</idno>
<idno type="wicri:doubleKey">0219-0494:2004:Yoon K:successful:usage:of</idno>
<idno type="wicri:Area/Main/Merge">001F60</idno>
<idno type="wicri:Area/Main/Curation">001F45</idno>
<idno type="wicri:Area/Main/Exploration">001F45</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title>
<author><name sortKey="Yoon, Kam Hon" sort="Yoon, Kam Hon" uniqKey="Yoon K" first="Kam Hon" last="Yoon">Kam Hon Yoon</name>
<affiliation wicri:level="1"><country xml:lang="fr">Singapour</country>
<wicri:regionArea>Department of Medicine, National University Hospital</wicri:regionArea>
<wicri:noRegion>National University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Singapour</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">APLAR Journal of Rheumatology</title>
<title level="j" type="alt">APLAR JOURNAL OF RHEUMATOLOGY</title>
<idno type="ISSN">0219-0494</idno>
<idno type="eISSN">1479-8077</idno>
<imprint><biblScope unit="vol">7</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="44">44</biblScope>
<biblScope unit="page" to="48">48</biblScope>
<biblScope unit="page-count">5</biblScope>
<publisher>Blackwell Science Pty</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2004-05">2004-05</date>
</imprint>
<idno type="ISSN">0219-0494</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0219-0494</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvantinduced arthritis</term>
<term>Adverse events</term>
<term>Antiphospholipid syndrome</term>
<term>Aplar journal</term>
<term>Arthritis</term>
<term>Arthritis rheum</term>
<term>Azathioprine</term>
<term>Azathioprine steroids</term>
<term>Chinese woman</term>
<term>Conventional therapy</term>
<term>Creatinine</term>
<term>Cutaneous manifestations</term>
<term>Cutaneous vasculitis</term>
<term>Cyclosporin</term>
<term>Disease conditions</term>
<term>Gastrointestinal symptoms</term>
<term>Good response</term>
<term>Immunosuppressive agents</term>
<term>Interstitial lung disease</term>
<term>Liver dysfunction</term>
<term>Liver function test</term>
<term>Lupus</term>
<term>Lupus erythematosus</term>
<term>Lupus nephritis</term>
<term>Malar rash</term>
<term>Mycophenolate</term>
<term>Mycophenolate steroids</term>
<term>National university hospital</term>
<term>Nephritis</term>
<term>Normal range</term>
<term>Partial responders</term>
<term>Patient example</term>
<term>Pediatric patients</term>
<term>Period november</term>
<term>Prednisolone</term>
<term>Psoriatic</term>
<term>Psoriatic arthritis</term>
<term>Renal biopsy</term>
<term>Renal transplantation</term>
<term>Resistant diseases</term>
<term>Rheum</term>
<term>Rheumatic diseases</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid arthritis patients</term>
<term>Rheumatology</term>
<term>Successful usage</term>
<term>Systemic lupus erythematosus</term>
<term>Tacrolimus</term>
<term>Topical tacrolimus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Aim:  This study reports the first successful usage of tacrolimus in various resistant or relapsed rheumatic diseases in Asian patients Methods:  This is an open prospective study of the efficacy of tacrolimus for patients with various relapsed/resistant rheumatic diseases who were intolerant of or failed conventional therapy. Patients were enrolled in the study from the period November 2001 to September 2002. Results:  A total of 20 patients were included in the study. Their disease conditions were as follows: SLE with relapsed lupus nephritis (six patients); SLE with antiphospholipid syndrome (APS) (two patients); rheumatoid arthritis (five patients); psoriatic arthritis (three patients); scleroderma (two patients); anti–Jo−1 syndrome (two patients). Improvement in their conditions were noted in all but one patient who was intolerant to tacrolimus. Conclusions:  Tacrolimus (FK506) is a new armamentarium that can be added to the choice of immunosuppressive agents for rheumatologists, especially for those patients with severe or resistant diseases.</div>
</front>
</TEI>
<affiliations><list><country><li>Singapour</li>
</country>
</list>
<tree><country name="Singapour"><noRegion><name sortKey="Yoon, Kam Hon" sort="Yoon, Kam Hon" uniqKey="Yoon K" first="Kam Hon" last="Yoon">Kam Hon Yoon</name>
</noRegion>
<name sortKey="Yoon, Kam Hon" sort="Yoon, Kam Hon" uniqKey="Yoon K" first="Kam Hon" last="Yoon">Kam Hon Yoon</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F45 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F45 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:34E26F591602D0871E1EC31B9D3729D0F17020C1
   |texte=   Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases

Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri